VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - March 5, 2006) - WEX Pharmaceuticals Inc. (“WEX” or the “Company”) (TSX:WXI) today announced the recommendation of the Data Monitoring Committee (“DMC”) following an interim analysis of its Canadian Phase IIb/III clinical trial of Tetrodotoxin (TectinTM), an investigational drug for the management of cancer-related pain.
